Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04088721
Recruitment Status : Recruiting
First Posted : September 13, 2019
Last Update Posted : September 13, 2019
Sponsor:
Collaborators:
Clinipace Worldwide
Taipei Medical University
Information provided by (Responsible Party):
Advagene Biopharma Co. Ltd.

Brief Summary:
A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Biological: AD17002 Other: Formulation Buffer Phase 1 Phase 2

Detailed Description:

A single center, double-blind, randomized, dose-escalation study to assess the safety, tolerability and efficacy of 3 doses of AD17002 in comparison to placebo. Subjects will be randomized at 3:1 ratios in each of 3 cohorts to receive AD17002 or placebo. The following treatment cohorts are featured in a dose-escalating manner:

A. Cohort 1 will comprise 16 subjects who will receive, in a double-blind manner, either 20 μg AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.

B. Cohort 2 will comprise 16 subjects who will receive, in a double-blind manner, either 40 μg AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.

C. Cohort 3 will comprise 16 subjects who will receive, in a double-blind manner, either 60 μg AD17002 (n=12) or placebo (n=4) on Study Day 1, 8, and 15.

A total of 16 subjects in cohort 1 will receive the assigned study preparation before the remainder of the Cohort. Study drug administration to the next subject for the first 8 subjects in the cohort 1 will be separated for at least one day elapse (at least 24 hrs). The progression to the next cohort will take place after the SRT review the whole follow-up period safety data of previous cohort.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Ib/IIa Randomized, Placebo Controlled, Intranasal Administration Study on Safety, Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With House Dust Mite (HDM) Allergic Rhinitis
Actual Study Start Date : March 26, 2019
Estimated Primary Completion Date : September 30, 2020
Estimated Study Completion Date : December 31, 2020

Arm Intervention/treatment
Experimental: AD17002 20μg
Intranasal weekly dosing of AD17002 for three times
Biological: AD17002
LTh(αK) as immunomodulator

Experimental: AD17002 40μg
Intranasal weekly dosing of AD17002 for three times
Biological: AD17002
LTh(αK) as immunomodulator

Experimental: AD17002 60μg
Intranasal weekly dosing of AD17002 for three times
Biological: AD17002
LTh(αK) as immunomodulator

Placebo Comparator: Placebo
Intranasal weekly dosing (placebo) for three times
Other: Formulation Buffer
Formulation buffer




Primary Outcome Measures :
  1. Safety and tolerance of LTh(αK) treatments in patients with HDM allergy as measured by incidence of adverse events [ Time Frame: up to 51 days. ]

Secondary Outcome Measures :
  1. Change in the total nasal symptoms score (TNSS) [ Time Frame: up to 51 days. ]

    Chang in Sneezing, Rhinorrhea, Nasal congestion / Blockage and Pruritus are recorded in diary and averaged.

    Severity is graded between 0-3 for each symptom. 0 = no symptoms 1 = mild symptoms (sign/symptom clearly present, but minimal awareness; easily tolerated) 2 = moderate symptoms (definite awareness of sign/symptom that is bothersome but tolerable) 3 = severe symptoms (sign/symptom that is hard to tolerate; causes interference with activities of daily living and/or sleeping)


  2. Change in the Rhinitis Daily Medication use Score (DMS) [ Time Frame: up to 51 days. ]

    Antihistamine oral form (Desloratadine 5mg/day) could be used in the evening, if the total reflective TNSS reaches to 8 points or greater.

    4 points addition to subjects take the antihistamine and 0 to subjects do not.


  3. Change in the the average of subject-reported combined TNSS and DMS [ Time Frame: up to 51 days. ]
  4. Change in the titers of HDM specific antibodies [ Time Frame: up to 51 days. ]
    The titers of specific antibodies, IgA, IgE, IgG and IgG4, are measured by ImmunoCap methods(Phadia 100).

  5. Change in the titers of Drug specific antibodies. [ Time Frame: up to 51 days. ]
    The titers of specific antibodies, IgA, IgE and IgG, are measured by ImmunoCap methods(Phadia 100).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 49 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

A subject can participate in the study only if all the following criteria are met:

  1. Subject 20-49 aged years, having a clinical history of allergic rhinitis (diagnosed by a physician) of 1 year duration or more and have received anti-allergy treatment during the previous year before the study enrollment.
  2. Subjects with HDM-specific IgE serum value ≥ 0.7 kUA/L during screening period.
  3. HDM allergic rhinitis symptoms during the baseline period defined as a total nasal symptoms score more than 6, at least on 5 of 7 consecutive calendar days in screening period. A subject receiving anti-allergy medication is required to washout of their medication before and during screening period of the trial until the required symptom threshold is met.
  4. No known prior clinical history of asthma.
  5. Subjects who are of reproductive potential agrees to remain abstinent or use (or have their partner use) an acceptable method of birth control within the projected duration of the trial. Acceptable methods of birth control are: intrauterine device, hormonal contraception, diaphragm with spermicide, contraceptive sponge, condom, vasectomy, as per local regulations or guidelines. Female subjects of childbearing potential must have negative serum pregnancy test at screening, and negative urine pregnancy test at randomization visit.
  6. A female subject who is not of reproductive potential and a male subject who is diagnosed to be sterile is eligible without requiring the use of contraception. A female subject who is not of reproductive potential is defined as: one who has either

    1. Reached natural menopause (defined as 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone levels in the postmenopausal range as determined by the laboratory, or 12 months of spontaneous amenorrhea),
    2. Six weeks postsurgical documented total hysterectomy and/or bilateral salpingo-oophorectomy, or
    3. Bilateral tubal ligation.
  7. Subject or the subject's legal representative understands the trial procedures, alternative treatments available, risks involved with the trial, and voluntarily agrees to participate by giving written informed consent.
  8. Be able to read, understand, and complete questionnaires and diaries.
  9. Provide written informed consent for the trial and willing to adhere to dose and visit schedules.

Exclusion Criteria:

Subjects who meet any of the following criteria are not eligible to enter the study:

  1. Has a clinically relevant, known history of symptomatic allergic rhinoconjunctivitis and/or asthma caused by mold, animal hair and dander, or other allergens (except HDM) to which the subject is regularly exposed and sensitized. Subjects without a known history of allergy other than to HDM, but show any positive result (on CAP test) towards the allergens could be accepted in the judgement of the investigator.
  2. Has any nasal condition that, in the judgement of the investigator, could confound the efficacy or safety assessments (e.g., nasal polyposis, nasal malformation, frequent nosebleeds, etc).
  3. Has a history of anaphylaxis reaction to any known or unknown cause.
  4. Has a history of chronic urticaria and/or angioedema within the last 2 years before Screening Visit.
  5. Immunosuppressed subjects as result of illness (e.g. HIV infection) or treatment.
  6. Has acute respiratory illness needing antibiotics or antivirals within 14 days prior to the Screening visit.
  7. Has acute sinusitis or chronic sinusitis accompanying acute symptoms within 3 days prior to administration of first dose of study drug.
  8. Has any clinically relevant chronic disease (≥3 months duration) [including but not limited to cystic fibrosis, malignancy, type I diabetes mellitus, malabsorption or malnutrition, renal or hepatic insufficiency, rheumatic arthritis, lupus and other autoimmune diseases].
  9. Has documented history of Bell's palsy.
  10. Has a history of allergic reaction to kanamycin.
  11. Has received Immunosuppressive treatment (ATC code L04 or L01) within 3 months prior to the Screening visit.
  12. Has had previous immunotherapy treatment with any HDM allergen.
  13. Has had previous exposure to the study drug or Flu Vaccine AD07030.
  14. Is receiving ongoing treatment with any specific immunotherapy at the time of the Screening Visit.
  15. Has a known history of allergy (except HDM), hypersensitivity, or intolerance to investigational medicinal products, rescue medications, or self-injectable epinephrine.
  16. Subjects with chronic (> 6 months) or intermittent dependence on nasal, inhaled, oral, intramuscular, intravenous corticosteroids, or potent topical corticosteroids with systemic effects. Subjects who are non-chronic users and do not use these corticosteroids intermittently must undergo at least 5 half-lives of washout prior to the Screening visit.
  17. Subjects using other medications for their allergic rhinitis and/or asthma if they cannot abstain from the specified time window below (or 5 half-lives, whichever is longer) prior to the Screening visit:

    • Nasal or oral antihistamines: 48 hours
    • Nasal decongestants: 24 hours
    • Oral decongestants: 24 hours
    • Short acting inhaled beta-agonists: 48 hours
    • Long acting antihistamine (half-life >24hrs): 10 days
  18. Subjects who had chronic use (> 6 months) of concomitant medications [e.g., tricyclic antidepressants, beta-blocker, xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates, leukotriene antagonists, 5-lipoxygenase inhibitors and long-acting inhaled beta-agonists, etc] that would affect assessment of the effectiveness of the investigational product. Subjects who are non-chronic users of these medications must undergo at least 5 half-lives of washout prior to the Screening visit.
  19. Is nursing at randomization and within the projected duration of the trial.
  20. Subject who plans travel outside the trial area for a substantial portion of the trial period.
  21. Other cases judged by the investigator to be ineligible for participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04088721


Contacts
Layout table for location contacts
Contact: Mingi Chang 88627970073 ext 21 mingi.chang@advagene.com.tw

Locations
Layout table for location information
Taiwan
Taipei Medical University Recruiting
Taipei City, Taiwan
Contact: Pei-ling Wu    +886-2-6638-2736    ohr@tmu.edu.tw   
Principal Investigator: Hanbin Kuo         
Sponsors and Collaborators
Advagene Biopharma Co. Ltd.
Clinipace Worldwide
Taipei Medical University
Investigators
Layout table for investigator information
Principal Investigator: Hanpin Kuo Taipei Medical University

Layout table for additonal information
Responsible Party: Advagene Biopharma Co. Ltd.
ClinicalTrials.gov Identifier: NCT04088721     History of Changes
Other Study ID Numbers: AD17002-AI01
First Posted: September 13, 2019    Key Record Dates
Last Update Posted: September 13, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases